Testing CNP-103 for newly diagnosed type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new study drug called CNP-103 for people ages 12-35 who were recently diagnosed (within 6 months) with stage 3 type 1 diabetes. The goal is to see if the drug can help preserve the body's ability to make some insulin, potentially slowing the need for more insulin shots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 to 35 years old
- You were diagnosed with type 1 diabetes within the last 6 months
- You are using insulin and have some remaining insulin production (C-peptide > 0.2 nmol/L)
- You are willing to avoid other diabetes medications and corticosteroids during the trial
- You weigh more than 77 pounds (35 kg) for the lower doses, or more than 110 pounds (50 kg) for the highest dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called GNTI-122 for adults recently diagnosed with type 1 diabetes who still make some insulin. It aims to see if the treatment can help protect the cells that produce insulin.
This study tests a new medication, MTX228, to see if it can help people with type 1 diabetes who still make some insulin. It may slow the loss of your own insulin production and improve blood sugar control.
This study tests if adding a non-insulin medication can lower the amount of insulin needed while improving heart and metabolic health in people with type 1 diabetes. It may also help understand how this approach works in people with a genetic form of diabetes (GCK-MODY).
This trial tests an investigational drug that may help preserve the body's ability to make insulin in people with type 1 diabetes. It aims to slow the progression of the disease and reduce the need for insulin injections.
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
This trial tests a new cell injection (CNK-UT009) for adults with type 1 diabetes. The goal is to see if it can help manage blood sugar and reduce insulin needs.
Hear when a new T1D trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.